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INTRODUCTION
Hepatocellular carcinoma  (HCC)  is  one  of  the  most  common  fatal  malignancies 
worldwide.  Incidence is more than 530,000 patients annually. It is common in certain geographic 
areas particularly in Japan, South East Asia, and Sub Saharan Africa. In India HCC is more 
common in southern states with a male female ratio of 5-7:1.  The prevalence of HCC is rapidly  
increasing as a result of the spread of chronic infections with Hepatitis B&C.
The main therapeutic modalities used for HCC are primary hepatic resection and loco 
regional  therapies.  Whenever liver function permits,  resection  should  be  considered the  first 
choice. But only less than 30 % of patients are suitable candidates for surgery and also 70% of 
patients who undergo surgery will develop new liver tumors during the first 3 years of follow up. 
Since most of the patients present in late stage, surgical options are not possible.  Hence loco  
regional therapies are the main stay in treatment. 
In  loco  regional  therapy,  liver  can  be  targeted  through  a  vascular  approach, 
injecting the active product through feeding vessels or by a direct approach to the tumor 
by delivering the treatment directly inside the mass lesion.
Loco regional therapy can be
 1) Vascular 
            2) Direct
Vascular Approach Procedures 
 Hepatic arterial chemotherapy
 Trans arterial chemoembolization (TACE) 
 Hepatic injection of  loaded embols (drug and radiation)
 Intra portal drug delivery
 Isolated liver perfusion
Direct Approach Procedures 
 Percutaneous ethanol injection(PEI)
 Radio frequency ablation(RFA)
 Cryo ablation
 Micro wave  and laser ablation
When the lesions are small  or less  than 3 in number with less  preserved hepatic reserve PEI /  RFA is  
indicated. In large lesions or more lesions with well preserved hepatic reserve TACE is indicated.
Chemoembolization combines simultaneous infusion of a concentrated dose of chemotherapeutic  drugs and 
embolization  particles.  Chemoembolization  causes  tumor  drug  concentration  manifolds  than  that  achieved  by 
infusion. Hepatic artery embolization renders the tumor ischemic, depriving it of nutrients and oxygen.  The dwell 
time of the chemotherapy agent within the tumor is markedly  prolonged, with measurable drug levels present as long 
as one month after procedure. Because most of the drug is retained    within the liver, systemic toxicity is reduced.
AIM
1. To  evaluate  the  role  of  Transarterial  chemoembolization  in  unresectable 
hepatocellular carcinoma patients as a palliative care.
This is done by assessing
• 1 year survival benefit of TACE patients.
• Pain reduction and performance status of TACE patients.
2. To assess the safety of TACE in unresectable HCC patients with portal  vein 
thrombosis.
REVIEW OF LITERATURE
Since  1977,  TACE  has  been  performed  in  Japan,  where  it  is  regarded  as  standard 
treatment in unresectable HCC. In Western nations, the procedure was introduced in the mid-
1980s. 
In 1989 Bockmeyer et al have done trans arterial chemoembolization of unresectable 
HCC  with  lipiodol  ,  epirubicin,  cisplatin   in  22  patients  and  repeated  TACE  after  storage 
subsided. They found 6 month ,12 month survivability of 73% and 54% respectively.
 Seven hundred thirty-nine patients with unresectable HCC have been treated by TACE 
using gelatin sponge particles soaked in a solution of Mitomycin C and Adriamycin by Uchida 
H, et al of Japan in 1990. They found this therapy can be equal or superior to surgical resection  
and serves both as embolic therapy and targeted chemotherapy.
In 1989 Nakamura H et al Japan, did TACE with doxorubicin hydrochloride, iodized oil, 
and gelatin sponge was used in 100 patients with HCC. They found TACE to offer better survival 
rate than chemo infusion. One year survival rate is 53%, 43% in chemoembolization and chemo 
infusion patients respectively.
In 1990 Uchida H et al7 Japan , carried out segmental Lipiodol-TAE in 54 patients with 
hepatocellular carcinoma .Better therapeutic results were obtained in 47 cases. They concluded 
that lipiodol -TAE doesn’t have adverse effect on the normal liver tissue.
In  1990  Pelletier  G et  al8, carried  out  randomized  trial  of  hepatic  arterial 
chemoembolization in 42 patients with unresectable hepatocellular carcinoma. Patients received 
either  repeated  chemoembolization  with  gelfoam  powder  and  doxorubicin  (group  1)  or 
symptomatic  treatment  (group  2).  They  noticed  no  significant  increase  in  survival  rate  in 
chemoembolization group even though partial response is noted in chemoembolization.
In 1991 Li GQ et al9 china, in their study included 60 cases of which  31 had Stage II and 
29  had  Stage  III  lesions.   Adriamycin  or  cisplatin  infusion  was  carried  out,  followed  by 
chemoembolization therapy of tumor vessels using mixture of ethiodized oil or iophendylate and 
mitomycin C. Finally, gelatin sponge block was used for proximal arterial embolization. After the 
treatment procedure, abdominal pain was relieved, tumor reduced in size, AFP, r-GT, AKP and 
LDH declined to various degrees and the survival time was prolonged. The 3-, 6- and 12-month 
survival rates were 93.3% (56/60), 67.3% (37/49) and 33.3% (9/27), respectively. It is indicated 
that  TAI  and  TAE,  being  safe  and  effective,  is  the  treatment  of  choice  for  patients  with 
unresectable HCC. 
Aoyama K et  al10,  in their study of  18 patients with hepatocellular carcinoma (HCC) 
treated by transcatheter arterial embolization (TAE) with a   4'-epi-doxorubicin (EDX)-lipiodol 
emulsion. Results are compared with TAE with gelfoam only. They noticed significant survival 
rates in TAE with doxorubicin.
Hasan et al in germany -50 mg/m2 epirubicin, 30 mg/m2 cisplatin, 8 ml fatty acid ethyl 
ester  of  iodinated  papaver  oil  and  10  ml  nonionic  contrast  medium  were  injected  under 
fluoroscopy into the proper hepatic artery in 16 HCC patients. Partial remission was achieved in 
10 patients after a median of 4 months. The median survival time was 9 months. 
In 1993  Park JH  et al11, in their study of TACE done  in 87 patients with recurrent 
HCC . One- and   2-year survival rates after TACE of the 87 recurrent HCCs were 74.7% and 
55% respectively. They found significant increase in survival rate when compared with control 
group. 
In  1993  Hashimoto  T et  al12,  The  anticancer  drug  adriamycin,  mixed  with  lipiodol 
injected via hepatic artery, accumulates in HCC and shows a good anti-cancer effect. TCE with 
Lipiodol also improved the prognosis. They found TCE without adding gelfoam had increased 
survival than symptomatic therapy.
In 1993  Daniels JR et al13 , performed Chemoembolization with 10 mg/mL of cross-
linked collagen, 10 mg/mL of mitomycin, 3 mg/mL of doxorubicin, and 3 mg/mL of cisplatin in 
ten  patients  of  HCC  with  portal  vein  thrombosis.  Eight  patients  responded  to  treatment, 
including two long-term survivors (> 2 years). They concluded that portal vein thrombosis should 
not  be  considered  an  absolute  contraindication  to  hepatic  chemoembolization.  Hepatic 
chemoembolization can be performed safely in the presence of adequate collateral circulation. 
In  1994  Lu  CD et  al14, studied  Fifty-two  patients  with  unresectable  hepatocellular 
carcinoma, Group A (n = 24) received lipiodolization with gelatin sponge and group B    (n = 28) 
lipiodolization alone. They found the therapeutic effects of lipiodolization without gelatin sponge 
for patients  with high risk were significantly  superior to those of  lipiodolization with gelatin 
sponge.  They  concluded  that  the  modality  of  hepatic  arterial  chemoembolization  should  be 
chosen according to the patient's clinical conditions.
In 1994 Bronowicki JP  et al15, studied TACE done in 127 advanced HCC patients. The 
results were compared with symptomatic therapy. Survival in the treated group were 64%, 38%, 
27%, and 27% at 1, 2, 3, and 4 years, respectively; those for the untreated group were 18%, 6%, 
and 5% at 1, 2 and 3 years, respectively (p < 0.0001). The survival was significantly increased in  
patients with Okuda Stage I and II disease (p < 0.0001), but not in those with Stage III. 
Katsumori T et al16, Segmental TAE was performed in nine patients with hepatic cirrhosis 
and advanced HCCs accompanied by portal vein thrombosis. The cumulative survival rates were 
67% at 6 months, 44% at 1 year, and 22% at 2 years. This therapeutic approach is thought to be 
a  useful  treatment  for  HCC  with  PTT,  because  it  reinforces  anticancer  effects  and  can  be 
performed more safely than conventional TACE.
In 1995  Yamada R et  al17, a  large series  of  1310 patients  noticed TACE and related 
procedures greatly increased survival benefits in unresectable HCC patients than resectable HCC 
patients. 
In 1996 Bayraktar Y et al18, mitomycin C mixed with Lipiodol and arterial embolization 
using  Gelfoam  was  done.  The  mean  survival  of  those  receiving  TACE  was  13.0  months. 
Chemotherapy without embolization yielded a mean survival of 7.2 months. The mean survival of 
the patients receiving no specific anti-cancer treatment was only 6.9 months. The mean survival 
of the group receiving TACE was significantly greater than that of either of the other two groups 
(p < 0.005).
Cheng L et  al19 , followed  the  effect  of  TAE on hepatocellular carcinoma .  In  there 
patients treated with TAE 1, 2, 3, 5, 7 years survival rates were 58.1%, 34.0%, 24.4%, 13.7%, 
9.1% .This results indicate therapy is a treatment of choice for patients with advanced HCC.
Rose DM ,  In 39 patients underwent TACE, overall actuarial survival was 35%, 20%, 
and 11% at 1, 2, and 3 years with a median survival of 9.2 months, which was significantly higher 
than over the group receiving supportive care only (p < 0.0001). Median survival for the group 
receiving supportive care was less than 3 months.
Kashima  Y TACE  did  TACE  in  three  advanced  HCC  patients  with  hepatic  vein 
thrombosis. They found significant reduction in size of tumor .
 In 2000  Mizoe A et al, did TACE in two patient with advanced HCC. Noticed gross 
reduction in tumor size. Following resection showed complete necrosis of tumor which indicates 
the efficacy of TACE. 
Caturelli E et al conducted TACE in 115 patients. They found TACE does not induce 
significant long-term worsening of liver function in patients with class A or B cirrhosis.
Roche A et al ,   found that TACE can be recommended in Okuda I or II patients, the 
sessions being prolonged after the second one only for the responders who do not present which 
severe side effects. 
Liu H et al  , did trans arterial chemoembolization in 40 HCC patients with portal vein 
thrombosis.  Follow  up  CT showed decrease  in  size  of  tumor thrombus 24patients  out  of  36 
patients. Survival is more than 1 year in 20 patients. They found TACE seems to be valuable for  
the treatment of intra portal tumor thrombi with massive HCC. 
Lo CM et al33 , From March 1996 to October 1997, 80 out of 279 Asian patients with 
newly diagnosed unresectable HCC treated with a variable dose of an emulsion of cisplatin in 
lipiodol  and  gelatin-sponge  particles  injected  through  the  hepatic  artery  (chemoembolization 
group, 40 patients) or symptomatic treatment (control group, 40 patients). Chemoembolization 
was repeated every 2 to 3 months unless there was evidence of contraindications or progressive 
disease.  Survival  was  the  main  end  point.  Chemoembolization  resulted  in  a  marked  tumor 
response, and the actuarial survival was significantly better in the chemoembolization group (1 
year, 57%; 2 years, 31%; 3 years, 26%) than in the control group (1 year, 32%; 2 years, 11%; 3 
years, 3%  ( p =.002 ). 
In 2002 Kim KM et al1, separated 182 patients who belong to child criteria A and  UICC 
stage T1-3N0M0, into two groups . One group was treated with chemoembolization and other 
group treated with hepatic resection. They found similar survival rates in both the groups.
Masutani et al28 , used four chemotherapeutic  agents including epirubicin along with 
lipiodol without embolization(chemolipidolization) ,and repeated every four week in a case of 
HCC with portal vein thrombosis patient  and good response was noted. 
In the study of Maeda S et al ,Complete and partial responses were obtained in 83 cases 
(53.2%) in the lipiodol-cisplatin suspension alone group compared to 60 cases (62.5%) in the 
lipiodol-cisplatin suspension and transcatheter arterial embolization group. The survival rate of 
the former was 29.6% at 5 years, and of the latter was 24.2% at 5 years
In  2003  Romano M, 30 found  a  intraarterial  administration  of  lidocaine  before  and 
during chemoembolization is a safe and effective method for preventing or reducing peri and post 
procedural pain and dosage of narcotic analgesics in patients with HCC with respect to group B 
patients.
In  2003  Wu  YP et  al, studied  the  efficacy  of  TACE  combined  with  portal  venous 
chemoembolization (PVCE) in the treatment of moderate and advanced stages of PLC. The half-
year survival rates were 93.1% in TACE/PVCE group and 72.0% in TACE group (P< 0.05). The 
1-year survival rates were 43.1% in TACE/PVCE group and 51.7% in TACE group.
In 2003 Schwartz JD, Beutler AS et al  reviewed 44 randomized trials investigating non-
embolization-based therapies in unresectable HCC. Hepatic artery infusion of [I]lipiodol appears 
safe;  initial  studies  suggested  a  survival  benefit  and  efficacy  comparable  to  more  toxic 
embolization-based therapies. Cytotoxic chemotherapy may confer a modest survival benefit in 
advanced  HCC  including  oral  fluoropyrimidines,  and  hepatic  arterial  or  i.v.  cisplatin  and 
doxorubicin.
In 2004 more recently published, well-conducted studies demonstrate a survival benefit 
conferred by TACE. Chemoembolization likely confers a benefit greater than that associated with 
embolization without chemical agents. There is limited evidence and consensus regarding optimal 
choice and dosage of chemical agents utilized for TACE.
Recently in  2005 Walser et al 37  in their study involving 42 patients of hepatocellular 
carcinoma with compromised portal  venous flow found TACE group survival is  longer when 
compared to control group who received symptomatic therapy alone (413 vs67 days). They used 
PVA particles, oily contrast, doxorubicin and mitomycinC. They compared the average tumor 
size, MELD score and survival data. 
In 2005,Georgiades et al36   in John Hopkins university , conducted study in 31 patients 
with unresectable HCC and portal vein thrombosis using Cisplatin , Mitomycin, Doxorubicin, 
Lipiodol ,  PVA particles and found median survival rate of 5.1months which was better than 
those who received symptomatic therapy alone.(3.7 months). They observed 5 months median 
survival rate in child class B and 12 months in child class A.
IMAGING AND VASCULAR ANATOMY OF LIVER
A thorough  knowledge  of  vascular  and  segmental  anatomy  of  liver  is  essential  for 
therapeutic planning, like segmental resection or loco regional therapies.
Vascular Anatomy39 
The liver receives 15 to 20% of the cardiac output and constitutes a significant reservoir 
for  blood.  The  liver  receives  dual  blood  supply  from  1)  the  hepatic  artery,  which  provides 
systemic arterial  circulation,  2)the portal  vein which returns blood from the spleen and gut. 
Arterial flow is primarily nutritive and provides about 20% of the blood supply; the remainder is 
supplied by the mesenteric portal drainage. The relative contribution of blood flow to the liver 
varies and depends upon hormones,  neural  stimulation (sympathetic,  vagal),  nutritional  state 
(including fasting or postprandial), and the presence of hepatic parenchymal disease. 
Hepatic Artery
The celiac artery gives rise to the common hepatic, splenic and left gastric arteries at the 
level of T12-L1. The common hepatic artery courses along the upper border of the pancreatic 
head, anteriorly and to the right, behind the posterior layer of peritoneum of the lesser sac. After 
giving the gastroduodenal artery, it continues along the upper margin of the duodenum as proper 
hepatic artery and enters the subperitoneal space of the hepatoduodenal ligament. It ascends to 
the liver anterior to the portal vein and medial to the common bile duct. After entering the porta 
hepatis, the proper hepatic artery divides into a right, a left and occasionally a middle hepatic  
artery. The right lobe is supplied by the right hepatic artery, the medial segment of the left lobe is 
supplied by the middle hepatic artery augmented by the branches of the left hepatic artery and 
the lateral segment of left  lobe receives blood from left hepatic artery. Branches of the right 
hepatic artery nourish the caudate lobe, but in some cases the left or even middle hepatic artery 
contributes.  The  right  hepatic  artery  also  gives  off  the  cystic  artery  which  supplies  the 
gallbladder. 
The vascular schema described above is present in only 55% of patients. Normal variants 
include (1) the right hepatic artery partially (18%) or completely (14%) replaced by superior 
mesenteric artery; (2) the entire hepatic artery arising from the superior mesenteric artery (2 to 
4%); (3) the left hepatic artery having a partially or totally replaced origin from the left gastric  
artery (18% to 25%); and (4) the left hepatic artery giving rise to the middle hepatic artery in 4-
5%.
Portal Vein
The main portal vein arises behind the pancreatic neck at the junction of the splenic and 
superior  mesenteric  veins.  The  main  portal  vein  courses  to  the  right  and  superiorly  in  the 
hepatoduodenal ligament, along with the hepatic artery and common bile duct, anterior to the 
foramen of Winslow.  At the porta hepatis, the portal vein divides into right and left branches. 
The  right  branch  of  portal  vein  courses  horizontally  before  bifurcating  into  anterior  and 
posterior branches. The left branch of portal vein is shorter as it ascends anterior to caudate lobe 
before  it  courses  ventrally  to  the  left  intersegmental  fissure,  where  it  divides  into  branches 
supplying the medial and lateral segments of the left hepatic lobe.
Hepatic Veins 
The hepatic veins lie in intersegmental & interlobar connective tissue. The right hepatic 
vein is usually the largest and courses obliquely between the anterior and posterior segments of 
the right lobe. The middle hepatic vein lies in between superior aspect of the right and left lobes. 
The left hepatic vein courses between the medial and lateral segments of the left lobe. All these 
veins course obliquely and superiorly and drain into the inferior vena cava, near its entrance into 
the right atrium. The right hepatic vein usually enters the inferior vena cava separately from the 
middle and left hepatic veins. The last two veins typically form a common trunk as they enter the 
vena cava.  
Lobar and Segmental Anatomy
The  segmental  anatomy  of  the  liver  is  eloquently  depicts  on  cross-sectional  imaging. 
Delineation of  this  anatomy is  essential  for the localization of  focal  hepatic  pathology before 
surgical,  angiographic  or  percutaneous  intervention.  Hepatic  segmental  topography  is  best 
appreciated  radiologically  by  identification of  the  vascular and fissural  anatomy.  The  portal 
venous, hepatic arterial and biliary radicles travel together within hepatic segments and lobes 
(intrasegmental). The main hepatic veins course between segments and lobes (intersegmental).
The right hepatic vein separates the posterior and anterior segments of the right lobe. The 
middle hepatic vein superiorly and the interlobar fissure inferiorly separate the right and left 
lobes of the liver. The medial and lateral segments of the left hepatic lobe are divided by three 
readily discernible structures: the ligamentum teres (inferiorly), the ascending portion of the left 
portal vein and the left hepatic vein (superiorly). 
Advances in surgical techniques and percutaneous intervention have popularized the use 
of the subsegmental anatomic classification of Couinaud, with the modification of Bismuth and 
colleagues, to define intrahepatic location more precisely. In this system, the liver is divided into 
one segment and eight  subsegments.  Segment 1 is  the caudate lobe.  The well-known vertical 
divisions along the planes of hepatic veins are maintained, but each segment is further divided 
into superior and inferior subsegments by a transverse fissure (a plane through the right and left  
portal veins). The subsegments are numbered in a clockwise fashion when viewing the liver in the  
frontal projection except for segment 4a. 
The caudate lobe is central hepatic lobe that has certain unique features. The anterior 
border of the caudate lobe is separated from the lateral segment of the left lobe by the fissure for  
the ligamentum venosum. The pars transversa of the left portal vein resides at the apex of this 
fissure.  Fat  in  this  fissure  often  communicates  with  fat  in  the  fissure  for ligamentum teres. 
Posteriorly caudate lobe is bordered by the inferior vena cava. Inferiorly caudate lobe forms the 
superior margin of foramen of Winslow.
HEPATOCELLULAR CARCINOMA
EPIDEMIOLOGY
HCC is the most common primary malignancy of the liver with a marked geographic 
variation .In terms of relative frequencies it ranks eighth in the world, seventh among men (5.6 
% of all cancer deaths) and eleventh among women (2.7 % of all cancer deaths). In developing 
countries it is the third most common cancer among men after stomach and lung cancer. Largest 
concentration is  found in Asia,  especially  in the coastal areas of South East Asia,  China and 
Japan.  Asia alone accounts for 70 % of all cases.   
It is common in South India. Male : Female ratio in India is 5-7:141. Mortality / Incidence ratio 
reported by the cancer registries is close to 1 indicating that majority of cases do not survive beyond 1 
year.
PATHOLOGY
Eggel classified HCC into three types.
I. Solitary massive 
II. Multicentric small nodular 
III. Diffuse infiltrating or cirrhotic form.
CLASSIFICATION BY HISTOLOGIC GRADES:
a) WELL DIFFERENTIATED HCC    
These are characterized by irregular thin trabecular patterns and fatty change. The HCC 
cells lack distinct cellular and nuclear atypia .Its common among HCCs < 2cms in diameter. It 
corresponds to grade I carcinoma of Edmonston – Steiner classification.
b) MODERATELY DIFFERENTIATED HCC
Classic  trabecular  pattern  with  tumor  cells  arranged  in  several  layers  and 
pseudoglandular patterns seen. This corresponds to grade II and III of the Edmonston –Steiner 
classification and is most common among advanced HCCs. 
C) POORLY DIFFERENTIATED HCC
These tumors show a compact solid growth pattern, loss of trabecular pattern increased 
nuclear cytoplasmic ratio and frequently show pleomorphism. Corresponds to Grade III and IV 
of Edmonston – Steiner classification.
d) UNDIFFERENTIATED CARCINOMA
The tumor cells  have scant cytoplasm with short  spindle shaped or round nuclei,  and 
proliferate in a solid or medullary pattern. This Corresponds to Stage IV of Edmonston – Steiner  
classification.
Based  on  histologic  features,  the  World  Health  Organization  has  classified  HCC  as 
trabecular, acinar, compact and scirrhous types.
Etiologic factors involved in pathogenesis
of Hepatocellular Carcinoma35
 
CLINICAL FEATURES
HCC is clinically silent in its early stages and the onset of symptoms is usually insidious.  
HCC developing in a liver without underlying chronic liver disease can grow to an enormous size, 
whereas HCC in a markedly shrunken cirrhotic  liver has no time to grow larger before the 
patient dies from hepatic failure.
Patients present with
1. Dull abdominal pain.
2. Malaise.
3. Anorexia.
4. Loss of weight, which is more common in HCC without cirrhosis 
         Weight loss greater than 25 % carries a poor prognosis.
5. Ascites – occurs in over half of cases and indicates a poor prognosis.
6. Palpable mass.
7. Jaundice is usually a late manifestation and it can be obstructive jaundice due to tumor 
extending into bile duct or due to lymph node causing obstruction of a major duct or  
hepatocellular jaundice due to hepatic failure.
8. Bone pain.
Berman described five patterns of clinical presentation 
A. Frank cancer.
B. Occult cancer.
C. Acute abdominal Cancer.
D. Febrile Cancer.
E. Metastatic Cancer.
A. Frank cancer 63 % - Signs and symptoms are referred to liver in patients with 
previously  good  health.  Clinical  presentations  are  asthenia,  loss  of  weight, 
abdominal pain, tender enlarged liver and jaundice. This was common in Japan 
before early detection by screening was introduced.
B. Occult  cancer 16 % -HCC was found during examination for complaints other 
than those attributable to liver.
C. Acute abdominal cancer 8 % - Most patients were in good health and suddenly 
developed features of an acute abdomen. Abdominal muscular exertion or forceful 
palpation would occasionally  precipitate  rupture of  a  superficial  tumor nodule. 
Hepatic  arteriography  will  demonstrate  the  bleeding  artery  and  it  should  be 
embolised. Immediate surgery results in 18 % survival rate, otherwise the outcome 
of acute bleeding of HCC is often fatal.
D. Febrile Cancer 8 % - The clinical picture is that of an enlarged liver abscess. A 
nodular abdominal mass with a tendency to central necrosis is noted. This form is 
usually  of  a  poorly  differentiated  HCC  with  sarcomatoid  feature.  It  is  most 
common in Africans.
E. Metastatic  cancer  –  5%  ,  The  symptoms  due  to  metastases  in  remote  organs 
completely  over  shadow  those  of  the  primary  lesion  and  may  be  the  only 
manifestation of an otherwise unsuspected HCC . Dissemination to lungs in early 
stages mimics tuberculosis, but there is a heavier distribution in lower zones.
HCC can be staged by using the Okuda staging system 35.
OKUDA  STAGING  SYSTEM  FOR  HCC  RELATE  TO  SURVIVAL       AFTER 
TREATMENT
1. Tumor hepatic replacement >50%
< 50 %
+
_
2. Ascites Present
Absent
+
_
3. Albumin < 3 g/dl
> 3 g/dl
+
_
4. Bilirubin >3 mg/dl
< 3 mg/dl
+
_
Median 
survival
Stage I All negative Not advanced 8.3 Months
Stage II 1 or 2 + Moderately advanced 2 Months
Stage III 3 or 4 + Very advanced 0.7 Months
Overall  Median 
survival
1.6 Months
            Because most patients with HCC have underlying cirrhosis, it is important to use clinical  
criteria to classify  the  severity  of  cirrhosis,  which has a considerable  bearing on therapeutic 
decisions. The Child classification system is usually used to stage cirrhosis into group A, group B, 
or group C. 
MODIFIED CHILD PUGH CLASSIFICATION FOR LIVER FUNCTIONAL STATUS 
Parameter
Score
1 2 3
Bilirubin (mg/dl) < 2.0 2.0 – 3.0 > 3.0
Albumin  (g/dl) > 3.5 2.8_ 3.5 < 2.8
Ascites None minimal Moderate to 
severe
Encephalopathy None mild Moderate to 
severe
Prothrombin 
time[seconds increased]
1-3 4-6 >6
Total numerical score                Child Pugh class
5-6 A
7-9 B
10-15                                             C 
Child Pugh group A disease has the best prognosis, and Child Pugh group C has the worst 
prognosis.
TNM    CLASSIFICATION
Tx  - Primary tumor cannot be assessed.
To  - No evidence of primary tumor .
T1  -  Solitary, less than 2 cms, without vascular invasion.
T2  - Solitary, less than 2 cms, with vascular invasion.
Multiple, single lobe involved, without vascular invasion.
Solitary, more than 2cms, without vascular invasion.
T3  - Solitary, more than 2 cms, with vascular invasion.
Multiple, single lobe less than 2cms, with vascular invasion.
Multiple, single lobe, 2cms.
T4  - Multiple, more than one lobe.
Invasion of major branch of portal or hepatic vein.
N0 - No nodal involvement
N1 - Presence of regional nodal involvement 
M0 - Indicates no distant metastasis 
M1 - Indicates metastasis present beyond the liver
STAGING
Stage I T 1 N 0 M 0
Stage II T 2 N 0 M 0
Stage III T 1
T 2
T 3
N 1
N 1
N 0/N1
M 0
M 0
M 0
Stage IV a T 4 N 1 M 0
Stage IV b Any T N 1 M 1
LABORATORY INVESTIGATIONS
Abnormal LFT with raised SGOT, SGPT, alkaline phosphatase, decreased albumin with 
the  exception of bilirubin  level corresponds to the severity of cirrhosis . Alpha-fetoprotein (AFP) 
is  elevated  in  75%  of  cases.  The  level  of  elevation  correlates  inversely  with  prognosis.  An 
elevation of  greater than 400 ng/mL predicts  HCC with specificity  greater than 95%. In the 
setting of a growing mass, cirrhosis, and the absence of acute hepatitis, many centers use a level  
greater than 1000 ng/mL as presumptive evidence of HCC (without biopsy).
IMAGING :
The role of imaging INCLUDES screening, diagnosis, staging, interventional therapy and 
post operative follow up.
          Diagnostic imaging depicts not only the primary hepatic disease but also ascites, lymph 
node metastases, and thrombosis of portal and or hepatic veins.
Morphologic features that are characteristic of HCC include the tumor capsule, internal 
mosaic pattern, venous invasion, fatty metamorphosis and occurrence within a cirrhotic liver. 
Presence of  capsule carries a better prognosis, as the tumors are amenable to surgical resection 
and also respond better to trans arterial chemo-embolization. The extent of tumor in relation to 
segmental anatomy and to surgically critical structures like IVC, major bile ducts and portal vein 
should be assessed.
Plain Radiograph: Plain films are nonspecific but may show a mass in the upper abdomen 
if the HCC is large. Rarely calcifications can be detected in HCC.
Ultrasonogram (USG) :
Ultrasonogram  is  the  most  commonly  used  screening  method  as  it  is  cheap,  widely 
available and non-invasive. Sensitivity ranges from 84 to 91 %., with most missed lesions being 
under 2 cms in diameter. Intraoperative ultrasound has 96 % sensitivity. Ultrasonography can 
detect extremely small tumors and when combined with serum alpha-fetoprotein assays, serves as 
an excellent screening method for high risk patients with long standing cirrhosis. Sonography, in 
conjunction with colour and duplex Doppler, is an excellent tool for diagnosing tumor thrombus 
in the portal and hepatic veins as well as the inferior vena cava. 
The most common finding is a discrete lesion of uniform echogenicity, usually hypoechoic 
or isoechoic and detected by the hypoechoic halo corresponding to the tumor capsule, mosaic 
pattern, septum formation and posterior echo enhancement also occur. Lesions less than 3 cms 
are usually hypoechoic.
In  tumors  with  diffuse  pattern,  disorganization of  normal  echo  pattern  with  multiple 
areas of increased and decreased echogenicity are seen throughout the distorted liver without 
distinct margins.
Hypoechoic lesion corresponds to a solid tumor without necrosis. Lesions with a mixed 
pattern are partially  necrotic.  Hyperechoic lesion is caused by fatty metamorphosis or severe 
sinusoidal dilatation .Fibrous septa and scars appear as hypoechoic linear structures. Ultrasonic 
documentation of venous involvement favors HCC over metastases. 
DOPPLER:
Colour Doppler ultrasound has been used to assess the vascularity of HCC because HCC 
tumour nodules are supplied by hepatic artery. Lesions show both intratumoral and peritumoral 
flow. A basket pattern (a fine blood flow network surrounding the tumour nodule) was observed 
in HCC. In lesions less than 2 cms it is difficult to detect the flow pattern. In lesions >2 cms, 
intralesional pulsatile flow with peak systolic velocity (PSV) more than 40 cms/s with relatively 
normal hepatic artery flow is strongly suggestive of HCC.. Arterial branches supplying HCCs 
tend to show an irregularly tortuous course,  and the tumour vessels  have widened, sclerosed 
lumina and shows increased PSV. Demonstration of hepatofugal flow and arterial flow within the 
thrombus by Doppler indicates a tumor thrombus.
COMPUTED TOMOGRAPHY:
Proper technical performance of CT with imaging in the hepatic-arterial, portal-venous 
phases and delayed-contrast phases are important in detecting HCC. CT appearance of HCC 
varies  depending  on  the  tumor  size  and  the  imaging  phase.  The  most  common  attenuation 
pattern  is  iso-hyper-isoattenuation  on  pre-,  arterial,  and  venous  phases,  respectively.  In  the 
hepatic-arterial  phase,  lesions typically  are hyperdense (relative to hepatic  parenchyma) as  a 
result of hepatic-arterial supply. In the portal-venous phase, small lesions may be isodense or 
hypodense and difficult  to  see,  since the remainder of  the liver also increases  in attenuation. 
Larger lesions with necrotic regions remain hypodense. In the delayed-post contrast phase, small 
lesions may be inconspicuous. Delayed phase scans may show a tumor capsule, one of the more 
specific signs indicating HCC. 
Tumor thrombus in  Portal  vein  and  IVC is  readily  depicted  but  subsequent  invasion 
through  the  vessel  wall  cannot  be  predicted.  Dynamic  CT  can  demonstrate  parallel  thin 
neovasculature along the vessel in tumor thrombus.
Endovenous tumor is persistently radiolucent, although arterial phase enhancement may 
occur  as  a  result  of  tumor  vascularity.  Frequently  there  is  linear  periportal  arterial  phase 
hypervascularity (TRAM – TRACK PATTERN) on contrast enhancement. Other signs of portal 
vein occlusion are straight line sign, and transient hepatic attenuation defects.
CT ARTERIOGRAPHY: (CTA)
It maximizes the principle of arterial phase contrast imaging. In patients with cirrhosis, 
CTA detects substantially more HCC nodules than helical arterial phase CT. Early and rapid 
tumor enhancement is directly related to angiogenesis .Increased microvessel density has been 
shown to correlate with poor prognosis, with higher rates of metastases and poor patient survival.
CT–ARTERIAL PORTOGRAPHY: (CTAP)
It is a sensitive technique for detection of HCC and metastases in non-cirrhotic patients.  
Contrast medium is selectively injected into SMA. This technique enhances normal parenchyma 
maximally while neoplasms supplied by the hepatic artery are enhanced minimally. Lesion as 
small as 0.5 cms can be detected .With severe cirrhosis and altered portal venous blood flow CT–
AP either fails to opacify the liver or results in too many “ pseudo-lesions” to be of clinical use .
LIPIODOL CT SCAN:
It can detect HCCs as small as 3.7 mm in diameter and this technique is predominantly 
used in Japan where it has been reported to be approximately as sensitive as CT-AP. About 4 to 
10 ml of lipiodol is injected into the hepatic artery and CT is done 7 – 14 days later. It is retained 
by  HCC  and  hypervascular  metastases.  Retention  is  due  to  the  absence  of  kuppfer  cells 
&lymphatics, hypervascularity and alteration in the sinusoidal spaces in HCC. Tumor vessels 
allow passage of substances with large molecules like macromolecular lipiodol than the vessels in 
normal tissue. Retention makes the nodules an excellent target for biopsy under CT guidance.
ANGIOGRAPHY:
Angiography is  a  useful  tool  in delineation of  arterial  anatomy before  surgery and in 
therapeutic applications like embolization and delivery of chemotherapeutic agents.
Angiography shows a hypervascular mass with neovascularity, enlarged tortuous feeding 
arteries, early draining vein and a marked tumor blush due to delayed clearance. Arterio-venous 
shunting  causes  early  opacification  of  portal  or  hepatic  veins  .Tumor  thrombus  is  directly 
demonstrated by a parallel thin neovasculature along the vessels (Thread and streaks sign) and 
indirectly as filling defect in the vessels. Small HCCs less than 2 cms are often hypovascular and 
may not be detectable by angiography.
MRI: 
HCC appearance varies on MRI depending on the multiple factors, such as hemorrhage, 
degree of fibrosis, histologic pattern, degree of necrosis, and the amount of fatty change. HCC on 
T1-weighted images may be isointense, hypointense, or hyperintense relative to the liver. On T2-
weighted images,  HCCs usually  are  hyperintense.  Pre and postcontrast  MRI have a 70-85% 
chance of detecting a solitary mass of HCC. MRI can help differentiate cirrhotic nodules from 
HCC. Gadolinium-enhanced MRI typically demonstrates that HCCs densely enhance, usually in 
the arterial phase and particularly if they are small. Visualization of the capsule (RIM SIGN) is 
characteristic of HCC .Capsule usually appears as a low intensity ring on T1W images or as an 
internal low intensity and external high intense ring on T2W images.
Gradient echo sequences are quite sensitive to changes in blood flow patterns and can 
identify tumor thrombus within IVC and portal vein.
MRI can differentiate a large regenerating nodule from a small HCC as the former is 
hypointense or isointense on T2W images.
In  the  diffuse infiltrative  form, the disease  is  more evident  in  T2W images  .A nodule 
within nodule  appearance suggests  early  HCC in a cirrhotic  liver .MRI seems to be slightly 
superior  than  contrast  enhanced  CT in  detection  of  lesions  2  cms  or  less  in  size.  Contrast 
enhancement and increased signal on T2W images are the imaging correlates of the increased 
microvascular density and vascular permeability that occurs with angiogenesis.
NUCLEAR MEDICINE:
 HCCs are usually depicted as a photopenic region on sulphur colloid scintigraphy. 70-90% 
of HCCs are gallium avid and moderately well differentiated tumors show the strongest uptake. 
99m Tc labeled macro aggregated albumin injected into hepatic artery demonstrates lesions as 
small as 5mm.
TREATMENT
In the presence of extra hepatic metastasis, intra arterial chemotherapy is indicated with 
no significant improvement in the survival. Hepatic resection is the treatment of choice when the 
tumor is smaller (<3 cms), < 3 in number, confined to one lobe, without involvement of hepatic  
vein and portal vein.  Hepatic transplantation is superior to hepatic resection, but the option is 
not easily available.
When  the  tumor  is  not  surgically  resectable,  loco  regional  therapies  play  a  major  role.  Locoregional 
therapies like PEI / RFA or TACE should be carried out, depending on the tumor size and numbers.
If the tumors are large( > 4cm)or more than 4 lesions or if the resection is not possible, and if the functional  
reserve  of  the  patients  is  good  as  indicated  by  Child  Pugh  criteria,  Trans  arterial  chemo  embolization  is  the 
treatment of choice.
If the lesion is smaller than 3cm and less than 3 in number with very poor functional  
reserve, PEI/ RFA are the only available options using chemical or physical destruction. RFA is 
more efficient than PEI.
Loaded Embols , These are recently introduced therapeutic materials, that  are used in the 
same  principle  of  chemo  embolization..  The  materials  used  are  glass  spheres  loaded  with 
yttrium_199 or gelatin spheres loaded with doxorubicin. 
Lastly 131 iodine – labeled lipiodol can be injected intra arterially for nonresectable HCC 
with portal vein thrombosis. It is also useful to lower recurrence after surgical resection. 
TREATMENT PROTOCOLS42
PROGNOSIS:
Prognosis  is  correlated  well  with  the  stage  of  the  disease  and  Child’s  score.  Serum 
bilirubin >2mg/dl and weight loss greater than 25% of body weight are the poorest prognostic  
factors. Other factors of predictive value include serum AFP values, IVC or portal vein invasion 
and presence of metastases.
Patients with advanced HCC live for an average of only one month from diagnosis .Okuda 
and  associates  reported  that  the  median  survival  of  patients  with  HCC who do  not  receive 
specific therapy was only 1.6 months. If limited to favorable conditions like Okuda stage I the  
median survival rate was 8.3 months35. 
TRANSARTERIAL CHEMOEMBOLIZATION
HCC is multifocal in 76% of patients, most of whom (81-87%) have underlying cirrhosis. 
The percentage of patients who are candidates for surgical treatment is 3-30%, depending on the 
series. Patients with small, uni nodular or binodular tumors smaller than 3 cm have the best  
outcome.  For  patients  undergoing  hepatic  transplantation,  the  3-year  survival  rate  without 
recurrence is 83%. The results of hepatic resection are poor. 
Effective  chemoembolization  of  the  liver  is  possible  because  of  the  following 
factors40.
1.  The liver has a unique pattern of blood supply. The portal vein supplies 75% of the 
hepatic  blood  flow,  while  the  hepatic  artery  supplies  the  remaining  25%.  This 
backup blood supply allows the occlusion of either vessel without resultant liver 
infarction. 
2.  95% of the blood for both primary and metastatic hepatic tumors is derived from 
the hepatic artery.
3.  The development of catheter technology allows the super selective placement of 
catheters for the safe and effective delivery of therapeutic agents to hepatic tumors. 
Microcatheters can be safely placed, even in the presence of aberrant vessels or a 
collateral blood supply. 
4. When  iodized  poppy  seed  oil  is  injected  into  the  hepatic  artery,  it  remains 
preferentially  in  the  neovascularity  of  HCC.  Therefore,  a  vehicle  exists  for 
delivering cytotoxic agents to tumor sites in the liver. Oily contrast droplets when 
released in hepatic artery selectively go into the largest arteries without entering 
the smaller one due to tensioactive forces.
5.  Water in oil emulsion that is chemotherapeutic drugs contained in oily contrast 
lipiodol,  selectively  enters  in  to  the  larger  tumor  vessel  and  then  releases  the 
chemotherapeutic agents into the tumor tissue.
6.  Lipiodol is responsible for temporary embolization of the arteries and of the portal 
system, which it  reaches through the peribiliary anastomosis, thus increases the 
dwell time between drug and tumor.
7. Embolization  after  chemo-lipiodol  increases  the  efficacy  of  chemotherapeutic 
agents  by providing additional  ischemia to the highly  hypervascularized tumor. 
This causes failure of transmembrane pumps, thus increasing the retention of the 
drugs inside the cells.
 8. Normally  Kupffer  cells  in  liver  actively  capture  and  phagocytose  iodized  oil 
droplets in hepatic sinusoids. Since there is absence of kupffer cells in hepatoma 
lipiodol is retained in the hepatoma for long time.
Chemolipiodol  embolization  and  gelfoam  embolization  are  done  separately  because 
chemolipiodol  particles  has  to  go  into   the  tumor  and from the  peribiliary  capillaries  goes 
retrogradely into the portal radicles causing the portal radicular occlusion. If gelfoam powder 
goes into the peribiliary plexus it causes biliary necrosis.
A further benefit is gained by regional arterial treatment, which results in lower systemic 
drug levels, thus reducing systemic toxicity. 
In our study TACE was done using the following methods
A protocol based on the technique used by Bismuth et al is used. 
Child  group  A  or  B  disease  are  considered No  extrahepatic  disease  should  be 
demonstrable.
Preparation:
All patients were given inj vitamin K 1 amp i.m one day prior to the procedure. The 
patient receives nothing by mouth beginning midnight before the procedure.
Pre medication :  
Inj Atropine
Inj  Chlorpheniramine maleate
Antibiotics prophylaxis :
Inj Cefotaxime 1 g iv bd 
Inj Metronidazole 500mg iv bd started one day prior to procedure
Sedation/ anesthesia :
Oral Lorazepam is used as  premedication to counter anxiety. It is given one hour prior to 
the procedure. Local anesthesia - xylocaine 2%.
The intra-arterial injection of 30-40 mg of 1% lidocaine is used for analgesia and given in 
the selective hepatic artery directed at embolization site to prevent  immediate  pain syndrome.
Patient positioning
Supine
Approach 
Percutaneous trans femoral
Technique    
Seldinger technique femoral puncture
Procedure 
Angiography  is  an  essential  part  of  the  workup  performed  prior  to  embolization  or 
chemoembolization. After the arterial  sheath catheter introduction, a celiac-axis and superior 
mesenteric angiogram is first obtained to identify common variations in the blood supply to the 
liver and to check for patency of the portal vein using 5-6F curved catheter (cobra). Selective 
cannulation  of  right  /  left  hepatic  artery  is  then  done..  Position  of  the  cystic  artery  and 
gastroduodenal arteries are  noted to avoid their embolization. Otherwise chemical duodenitis, 
chemical cholecystitis can occur. Catheter is advanced as close to the tumor as possible, if not it is  
advanced up to the segmental level hepatic artery branches. Even if this is not possible due to 
lack of micro catheters then the main catheter is advanced into the right main hepatic artery 
distal to cystic artery origin or into the left hepatic artery.
Chemotherapeutic emulsions are released into the feeding vessels i.e. segmental or right 
main or left main artery depending upon the catheter placement. 
After the release of chemotherapeutic agents embolization is done separately using the gel 
foam pledgets. After the procedure, catheter is removed and the puncture site is compressed and 
dressed after attaining hemostasis. 
Post procedural follow up 
All the patients were followed up as inpatients and IV antibiotics continued for 3 days. 
Patients are discharged on fourth day if there is no serious complication.
Chemo embolizing material :
Chemo therapeutic agents : Cisplatin (alkylating agents) 20mg/m2 
Adriamycin (anti tumor antibiotic) 20mg/m2 
Vehicle medium : Omnipaque  300mg  ( 5 ml)
Lipiodol  (8 -10ml   )                                                           
Emulsion preparation:
Both  adriamycin  powder and cisplatin are mixed  with   water soluble contrast  medium 
(omnipaque). This mixture is mixed with lipiodol by alternate filling and emptying using three 
way stopcock with two syringes.
Embolising material
Gelfoam, a water insoluble temporary  haemostatic material prepared from purified skin 
gelatin  (a  non antigenic  carbohydrate),  is  frequently  used as  a biodegradable,  intravascular 
embolic agent. Correll and Wise were the first to report the haemostatic properties of Gelfoam. 
Histologically , Gelfoam initiates an acute full thickness necrotizing arteritis of the arterial wall 
and leads to thrombus formation. Gelfoam is currently available in a sheet from which sections of 
various size can be cut. Gelfoam, like polyvinyl alcohol, is not  radio opaque and is typically  
mixed with iodinated contrast material before injection. The small size of the particles in gelfoam 
powder increases the risk of ischemia caused by the distal artery occlusion, eventually leading to 
biliary necrosis. So it is now recommended that gelfoam powder should not be used.
Pledgets cut from a sheet of gelfoam are typically larger and result in a more proximal 
occlusion.  An additional technique is to create gelfoam slurry by mixing pledgets between two 
syringes via a three-way stopcock. This method will decrease the size of the injected gelfoam and 
allow a more distal delivery than that achieved with pledgets.  The arterial occlusion induced by 
gelfoam is often recanalized with in weeks to months of the embolization procedure. Poly vinyl 
alcohol particles can be used. They cause permanent occlusion of vessels.
Complications:
Embolization of  solid  organs  causes  a  self-limited  postembolization  syndrome in  the 
majority of patients, consisting of varying degrees of pain, nausea, vomiting, and fever. This is 
independent of chemotherapeutic drug used, reason for embolization (eg, bleeding, tumor), and 
the organ treated (eg, liver, kidney, spleen, uterus). With current medical care (eg, hydration, 
antiemetic therapy, and pain control), postembolization syndrome is well tolerated.
Liver function is  transiently  affected with an increase in  liver aminotransferase levels. 
These values usually peak 3–5 days after therapy and return to baseline levels by  10–14 days after 
embolization. There is no sustained degradation of liver function in properly selected patients. 
Because most of the injected drug is retained in the liver, systemic toxicity is minimized, with little 
bone  marrow  suppression.  Serious  adverse  events  occur  after  approximately  5%  of 
chemoembolization procedures. The most common serious adverse events are liver abscess or 
liver infarction, which occur in approximately 2% of cases each. The 30-day mortality rate is 1%.
The major complications as noted by   Sakamoto et al in 2300 patients in 1998 are, Acute 
hepatic failure (0.26%), Liver abscess (0.22%), Intrahepatic biloma (0.87%), Hepatic infarction 
(0.17%), Multiple intrahepatic aneurysms (0.26%), Cholecystitis/gallbladder infarction (0.30%), 
Splenic  infarction  (0.08%)  Gastrointestinal  mucosal  lesion  (0.22%),Pulmonary 
embolism/infarction (0.17%), Tumor  rupture (0.04%).
Comparison of TACE with other techniques 
Percutaneous ethanol instillation (PEI) 
It is  usually performed in patients with cirrhosis and HCC. Candidates for ethanol ablation must have 
tumors with a volume less than 30% of the total volume of the liver. Contraindications for this procedure include  
portal vein thrombosis, extrahepatic disease, Child group C, a prothrombin time more than 40% increase, and a 
platelet count less than 40,000/mm3.PEI is inexpensive, easy to perform, and repeatable. Long-term results of PEI 
and surgery in the treatment of small-to-medium sized HCCs are comparable. 
In multiple HCCs,  ethanol  is  less  toxic  than chemoembolization.  PEI is  currently considered a reliable  
alternative to surgery in the management of limited-stage cancer, but unlike TACE, it is not suitable for multifocal  
advanced disease.  Unlike with TACE, necrosis of  the capsule and perineoplastic tissue have occurred with PEI.  
Shiina and Niwa described survival rates with a potentially curable HCC treated with PEI in 131 patients at 1&2  
years as 87%&70% respectively.
Radiofrequency Ablation 
It is suitable for patients with 4 or fewer primary or metastatic liver tumors 5 cm or smaller. The tumors  
should be completely surrounded by liver parenchyma, they should be at least 1 cm deep to the liver capsule, and  
they should be at least 2 cm or more away from major intrahepatic portal and hepatic veins. Subcapsular tumors can 
be ablated, but in this situation, the procedure causes more pain. RF ablation performed in tumors near the porta 
hepatis poses an increased risk of injury to the bile ducts and portal vein and it is generally more painful. Patients  
with sepsis, severe debility, and coagulopathy usually cannot be treated by using RF ablation. 
In a prospective study of small HCCs, Livraghi and associates have shown that the rate of complete ablation 
was 10% higher with RF ablation than with ethanol ablation. Unlike ethanol ablation, RF ablation appears to be 
effective in treating both HCCs and liver metastases. RF ablation is less toxic than agents used in TACE and it is  
better controlled. The main disadvantage of RF ablation is the difficulty in heating normal liver tissue, and hence,  
tumors have a higher recurrence rate than desired. 
Bartolozzi et al noted, when combining TACE and PEI, the overall survival rates at 1, 2years were 92%, 
83% respectively. These figures appear to be more positive than the results achieved with TACE or PEI alone.  
Chemoembolization as a bridge to transplantation:
The prevention of  progression of the HCC until  a donor liver becomes available is  in the patient’s  best 
interest.  Chemoembolization plays a critical  role in permitting eventual cure in this patient subset by inhibiting  
tumor growth so that patients can remain on the transplant list.
MATERIALS AND METHODS
This prospective study was done in Barnard Institute of Radiology during the period, Dec 
2003 to  Dec 2005.  The patients  were  referred  from various  Government  medical  colleges  in 
Chennai. 
Forty  two patients  in the age  group of  35 to 73 years  who either refused to undergo 
surgery  or  were  denied  surgery  due  to  poor general  condition  or  due  to  contra-indications 
irrespective  of  portal  vein involvement were chosen.  Of  these  forty  two patients,  16  patients 
underwent TACE and the remaining 26 patients were treated conservatively. Both these groups 
were selected in a nonrandomized manner.
Criteria   for Inclusion were
Mass more than 4 cm size
More than 4 lesions
Childs Pugh  A, B 
Criteria   for Exclusion  were
Childs Pugh C 
Extra hepatic metastasis
The diagnosis  of  HCC was  established  with  USG  guided   biopsy  and  in  some cases 
combining classical imaging finding with alpha protein level more than 1000 ng/ml.
All forty two patients underwent pretreatment ultrasound, duplex, dual phase CT to know 
the tumor size, extension, portal vein involvement & hepatic vein involvement.
Other parameters necessary for Child Pugh criteria, that is presence of ascites, bilirubin 
level, prothrombin level, albumin level, encephalopathy status are also noted. Cardiac profile was 
done in all patients. 
After selecting the patient, all the sixteen patients in the interventional group underwent 
trans arterial chemo embolisation with cisplatin , adriamycin, lipiodol & gelfoam. Angiography 
and embolization was performed using a 800MA conventional angiographic unit (siemens). 26 
patients  in  the  conservative  group  were  given  symptomatic  therapy  including  intra  venous 
chemotherapy. In those patients with main portal vein involvement (n=3) TACE was done with 
out adding gelfoam  (chemo lipiodolization)  Repeat TACE was done in patients with no adverse  
reaction to prior TACE.
All the patients were admitted one day prior to the procedure and discharged 3 days after 
the procedure. All the patients were followed up for 12 months. 
Many of the patients presented with severe upper abdominal pain. In all patients pain 
intensity was classified by visual analogue scale using 0- 10 criteria starting from least possible 
pain to worst possible pain.
Performance status of the patients were scored using performance status scale by ECOG. 
Visual  analogue  scale  and performance  status  score  were  noted  in  all  the  patients  both  pre 
procedurally  and  post  procedurally  after  one  month.  Contrast  enhanced  CT and  USG with 
Duplex sonography were done one month after treatment to asses the tumor size and lipiodol 
retention.  Change  in  tumor size  in  single  long  axis   (  RECIST )was  taken as  a  measure of 
response to treatment in  contrast enhanced CT as noted by Therasse p et al was taken .
RESULTS AND ANALYSIS
TABLE 1
SEX  DISTRIBUTION
SEX
Treatment
TotalTACE Symptomatic
Count % Count % Count %
Male 14 87.5 22 84.6 36 85.7
Female 2 12.5 4 15.4 6 14.3
Total 16 100.0 26 100.0 42 100.0
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TABLE 2
AGE WISE DISTRIBUTION
Age
Treatment
TotalTACE Symptomatic
Count % Count % Count %
30 - 40 1 6.3 0 0.0 1 2.4
40 - 50 5 31.3 5 19.2 10 23.8
50 - 60 8 50.0 11 42.3 19 45.2
60 - 70 2 12.5 9 34.6 11 26.2
70 - 80 0 0.0 1 3.8 1 2.4
Total 16 100.0 26 100.0 42 100.0
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TABLE 3
CLINICAL FEATURES
Upper abdominal Pain 14 33%
Constitutional Symptoms 26 62%
Palpable mass 8 19%
Ascites 14 33%
Jaundice 17 40%
Asymptomatic 2 5%
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TABLE 4
PORTAL VEIN INVOLVEMENT
Portal Vein status
Treatment
TotalTACE Symptomatic
Count % Count % Count %
Normal 9 56.3 9 34.6 18 42.9
Branch vein 4 25.0 9 34.6 13 31.0
Main portal vein 3 18.8 8 30.8 11 26.2
Total 16 100.0 26 100.0 42 100.0
TABLE 5
CHILD PUGH CRITERIA DISTRIBUTION
CHILD 
PUGH 
criteria
Treatment
TotalTACE Symptomatic
Count % Count % Count %
A 10 62.5 10 38.5 20 47.6
B 6 37.5 16 61.5 22 52.4
Total 16 100.0 26 100.0 42 100.0
TABLE 6
COMPARISON OF VAS & PSS BEFORE AND
AFTER TREATMENT
TACE Symptomatic
t df p valueN Mean S D N Mean S D
Pre VAS 16 5.81 1.52 26 5.38 1.65 0.84 40 0.405
Pre PSS 16 2.00 0.63 26 2.54 1.03 -1.88 40 0.067
Post VAS 16 3.81 0.83 23 6.22 1.70 -5.21 37 0.000
Post PSS 16 1.94 0.57 23 2.83 0.83 -3.69 37 0.001
 Visual anolog scale
0
2
4
6
8
10
prevas postvas
TACE
Symptomatic
Performance status scale
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4
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TABLE 7
TUMOR SIZE REDUCTION 1 MONTH AFTER THERAPY
Tumor Size
Treatment
TotalTACE Symptomatic
Count % Count % Count %
No change 7 43.8 8 34.8 15 38.5
Reduced 9 56.3 0 0.0 9 23.1
Increased 0 0.0 15 65.2 15 38.5
Total 16 100.0 23 100.0 39 100.0
p < 0.001
TABLE 8
6 MONTH FOLLOW UP SURVIVAL
Follow up 6 
months
Treatment
TotalTACE Symptomatic
Count % Count % Count %
Survived 14 87.5 9 34.6 23 54.8
Died 2 12.5 17 65.4 19 45.2
Total 16 100.0 26 100.0 42 100.0
p < 0.01
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TABLE 9
6 MONTH FOLLOW UP RELATING TO CHILD
PUGH CRITERIA
Follow  up 
6 months
CHILD PUGH criteria
TotalA B
Count % Count % Count %
Survived 15 75.0 8 36.4 23 54.8
Died 5 25.0 14 63.6 19 45.2
Total 20 100.0 22 100.0 42 100.0
p < 0.05
TABLE 10
6 MONTH  FOLLOW UP RELATING TO 
PORTAL VEIN STATUS
Follow up 
6 months
Portal Vein status
TotalNormal Branch vein
Main portal 
vein
Count % Count % Count % Count %
Survived 15 83.3 6 46.2 2 18.2 23 54.8
Died 3 16.7 7 53.8 9 81.8 19 45.2
Total 18 100 13 100 11 100 42 100
p < 0.01
TABLE 11
12 MONTH FOLLOW UP
Follow  up 
12 months
Treatment
TotalTACE Symptomatic
Count % Count % Count %
Survived 9 56.3 2 7.7 11 26.2
Died 7 43.8 24 92.3 31 73.8
Total 16 100.0 26 100.0 42 100.0
p < 0.01
TABLE 12
12 MONTH FOLLOW UP RELATING TO
CHILD PUGH CRITERIA
Follow  up 
12 months
CHILD PUGH criteria Total
A B
Count % Count % Count %
Survived 11 55.0 0 0.0 11 26.2
Died 9 45.0 22 100.0 31 73.8
Total 20 100.0 22 100.0 42 100.0
p < 0.001
TABLE 13
12 MONTH FOLLOW UP RELATING TO
PORTAL VEIN STATUS
Follow up 
12 
months
Portal Vein status
TotalNormal Branch vein
Main portal 
vein
Count % Count % Count % Count %
Survived 10 55.6 1 7.7 0 0.0 11 26.2
Died 8 44.4 12 92.3 11 100 31 73.8
Total 18 100 13 100 11 100 42 100
p < 0.01
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Table 14
COMPLICATIONS
NIL 7
Post embolization syndrome 7
Liver abscess 2
Liver cell failure 1
Catheter related complication 1
 
Complication
38%
39%
11%
6%
6%
NIL
Post embolizat ion
Liver abcess
Liver cell failure
Catheter related complicat ion
Table 15
12 MONTHS SURVIVAL, PORTAL VEIN STATUS
AND TREATMENT CROSS TABULATION
Follow up 12 months
Treatment Total
TACE
Symptomati
c
Survived
Portal Vein 
status
Normal 8 2 10
Branch vein 1 0 1
Total 9 2 11
Died
Portal Vein 
status
Normal 1 7 8
Branch vein 3 9 12
Main portal 
vein 3 8 11
Total 7 24 31
p value not significant
Table 16
6 MONTHS SURVIVAL, PORTAL VEIN STATUS
AND TREATMENT CROSS TABULATION
Follow up 6 months
Treatment
TotalTACE
Symptomati
c
Survived
Portal Vein 
status
Normal 9 6 15
Branch vein 4 2 6
Main portal 
vein 1 1 2
Total 14 9 23
Died
Portal Vein 
status
Normal 0 3 3
Branch vein 0 7 7
Main portal 
vein 2 7 9
Total 2 17 19
p value not significant
TABLE 17
6 MONTHS SURVIVAL, CHILD PUGH CRITERIA AND TREATMENT CROSS 
TABULATION
Follow up 6 months
Treatment
TotalTACE
Symptomati
c
Survived
CHILD PUGH 
criteria
A 9 6 15
B 5 3 8
Total 14 9 23
Died
CHILD PUGH 
criteria
A 1 4 5
B 1 13 14
Total 2 17 19
p value not significant
TABLE 18
12 MONTHS SURVIVAL, CHILD PUGH CRITERIA AND TREATMENT 
CROSS TABULATION
Follow up 12 months
Treatment
TotalTACE
Symptomati
c
Survived
CHILD PUGH 
criteria A 9 2 11
Total 9 2 11
Died
CHILD PUGH 
criteria
A 1 8 9
B 6 16 22
Total 7 24 31
 
DISCUSSION
In our prospective study group of 42 patients, the age range was 35 to 73 years with mean 
age being 55 years. But in western countries, the incidence of hepatocellular carcinoma is more 
common between 60 to 70 years. Early incidence is due to increase in infection rate of hepatitis B 
& C virus.
In 42 patients 36 patients were men and 6 patients were women with the male: female  
ratio of 6:1. This is comparable to the western incidence.
In my study, 33% patients presented with upper abdominal pain, 62% patients presented 
with constitutional symptoms like weight loss , malaise, 19% patients presented with palpable 
liver mass,  33% patients  presented with  ascites,  40% presented  with  jaundice  .  Majority  of 
patients presented with symptoms, constitutional symptoms being more common. In contrast to 
our  study,  asymptomatic  presentation  is  more  common  in  Japan  due  to  active  screening 
programme.
Of the forty two patients TACE was done for 16 patients, the remaining 26 patients were  
treated with symptomatic therapy. 20 patients belonged to Child Pugh criteria A, 22 patients 
belonged to Child Pugh criteria B. Of these 20 patients with Child Pugh criteria A, 10 patients 
were treated with TACE. Six patients out of 22 Child Pugh criteria B patients were treated with  
TACE.
In sixteen patients of TACE group 9 patients had patent portal vein, 4 patients had branch 
vein thrombosis, 3had main portal vein thrombosis. In patients with main portal vein thrombosis 
embolization with gelfoam was not done, only chemolipoidolization was done.
In twenty six patients of symptomatic treatment group 9 patients had patient portal vein,  
9 patients had branch vein thrombosis, 8 patients had main portal vein thrombosis.  
Most of the patients tolerated well to the procedure, with post embolization syndrome 
noted in 7 (43%), liver abscess in 2(12%), liver cell failure in 6% (1), puncture site hematoma in 1 
(6%)  patients.  The  liver  cell  failure  patient  died  in  35  days  after  TACE  from  intractable 
gastrointestinal hemorrhage. Proportion of major complications (were higher in our study than 
Sakamoto et al study (5%) probably because of small study group and inclusion of main portal 
vein thrombosis in our study.
Partial response as indicated by the size of the tumor reduction by more than 20% was 
noted in (6) 38% patients. Stable disease indicated by no change in size of the tumor was noted in 
7(44%) patients.  Progressive disease indicated by increase in size of tumor of at least 20% was 
noted in 3 (18 %) patients in TACE group. While in symptomatic treatment group, none of the 
patients showed reduction in the size of the tumor, 8  (35%) patients showed no change  in size 
(stable  disease),  and  15  (65%)  patients  showed  increase  in  the  size  of  the  tumor.  TACE of 
unresectable  HCC  produced  significant  reduction  in  size  of  tumor  than  symptomatic 
management with statistical significance. (p <0.05)
 Analysis showed significant reduction of VAS score in TACE group when compared with 
symptomatic  management  group.  The  mean  VAS  score,  pre  &post  treatment  in  TACE  and 
symptomatic group are 5.8, 3.8 and 5.3, 6.2 respectively. In TACE group reduction of pain was 
more in Child Pugh A than B with statistical significance (p<0.01).
Performance status scale showed mild improvement in TACE group than symptomatic 
group. The mean PSS score in pre & post treatment group being 2 &1.94 in TACE group, 2.5 
&2.8 in symptomatic management group which is statistically significant with p value < 0.001. So 
TACE showed  mild  improvement  of  the  performance  status  of  the  advanced  hepatocellular 
carcinoma patients.
In TACE group 14 out of 16 patients survived beyond 6 months. Whereas in symptomatic 
therapy group only 9 out of 26 patients survived beyond 6 months.  6 months survival rate was 
87.5% in TACE group. 6 month survival rate of TACE patients with Child Pugh A & B criteria  
were 90%& 83% respectively. In symptomatic therapy 6 months survival rate was 60% &18% in 
Child Pugh A &B criteria patients respectively.
 In TACE group, 9 out of 16 patients survived beyond 12 months with 12 month survival 
rate of 56%. All survived patients belonged to Child Pugh A.  None of the Child Pugh B patients 
survived beyond 10 months. In symptomatic therapy group only 2 patients out of 26 survived 
beyond 12 months with survival rate of 7%.
 Solomon  et  al,  in  their  study  of  38  patients  with  Okuda  stage  2  who  underwent 
chemoembolization  noted  that  the  one  year  and  two  year  survival  rate  as  60  %  and  41% 
respectively. In our study one year survival rate was 56%.
In Brown et al, study of 81 patients, chemoembolization produced one year and two year 
survival rates of 61% and 42%. Our study produced similar one year survival results. 
Lo  et  al,  compared  survival outcomes  of  chemoembolization  versus  symptomatic 
management, with 40 patients per group. One, 2-, and 3-year survival rates  in the study group 
were 57%, 31%, and 26% compared with 32%, 11%, and 3% in the control. 1 year survival rates 
were comparable with our study.
In patients without portal vein involvement, 6 &12 month survival rates were 83% &55% 
respectively, whereas in portal vein branch involvement patients 6&12 month survival rates were 
46%&7% respectively. In main portal vein thrombosis 6&12 month survival rates were 18% &0. 
Our  study  showed  portal  vein  status  was  one  of  the  main  prognostic  factors  in  HCC 
management.  
Further analysis showed 6 month survival rate in patent portal vein patients , branch vein 
involved patients, main portal vein involved patients being 100%,100%,33% and 88%,22%,12% 
in TACE and symptomatic therapy patients respectively. 12month survival rate in patent portal 
vein patients, branch vein involved patients, main portal vein involved patients were 88%, 25%, 
0%and 25%, 0%, 0% in TACE and symptomatic therapy patients respectively.
Even though statistical analysis showed no significant association, median survival rate of 
9 months in portal vein involved patients treated with TACE group was noted, whereas it was 3  
months in symptomatically treated patients group. In Child Pugh A group patients treated with 
TACE the median survival rate was more than 12months, whereas in symptomatically treated 
patients it was 7.5 months. In Child Pugh B group patients treated with TACE and symptomatic 
management, the median survival rates were 7 and 2 months respectively.
This median survival rates were compared with Georgiades et al study in John Hopkins 
University. They studied 31 patients with unresectable HCC with portal vein thrombosis patients. 
They  did  TACE  using  Cisplatin  ,  Mitomycin,  Doxorubicin,  Lipiodol  and  PVA. They  found 
median  survival  rate  of  5.1  months  for  TACE  group  as  compared  to  3.7  months  in 
symptomatically treated group. They observed median survival rate in Child Pugh class A & B as 
12 and 5 months respectively. In our study median survival rate was slightly more in all groups 
except in symptomatically treated portal vein involved patients. 
SUMMARY
In our study of 42 unresectable HCC patients TACE was done in 16 patients, remaining 26 
patients treated with symptomatic therapy.
Of these 16 TACE patients 10 patients belonged to Child Pugh A remaining 6 patients 
belonged to Child Pugh B and 7 patients had portal vein involvement.
TACE  was  done  using  cisplatin,  adriamyin  ,lipiodol,  gelfoam  .Remaining  26  patients 
treated symptomatic therapy.
Significant  reduction  of  VAS  score  in  the  TACE  group  of  patients  improved 
symptomatically treated patients (p<0.05).
TACE  group  patients  showed  significant  improvement  in  performance  status  than 
symptomatically treated patient (p <0.01).
In our series liver cell failure was noted in one patient in TACE group immediately after 
embolization & died in 30 days after the procedure.
6 month survived rate, increased from 60% in symptomatically treated patients to 87.5% 
in TACE group patients.
One year survival rate, increased from 7 % in symptomatically treated patient to 50% in 
TACE group of patients. All survived patients belonged to Child Pugh A criteria with statistical 
significance.
Median survival rate in Child Pugh A criteria patients were higher in TACE group (>12 
months) than symptomatically treated patients (7 months). In Child Pugh “B” criteria TACE 
produced same results.
Even though there  was no statistical  significance portal  vein involved patients  showed 
prolongation of median survival rate in TACE group (9months) than symptomatically treated 
patients (3 months).
CONCLUSION
Transarterial  Chemoembolization  of  unresectable  hepatocellular  carcinoma  (n=16)  is 
useful  in palliative care as indicated by improvement in performance status score and visual 
analogue pain scale when compared to symptomatic management (n=26).
Transarterial chemoembolization prolongs the survival of the patients with unresectable 
hepatocellular carcinoma when compared to symptomatic management.
Selective embolization of advanced hepatocellular carcinoma proves safe in the presence 
of portal vein thrombosis.
So in the present scenario where our patients present in late stage of HCC, TACE should 
be offered as a palliative procedure to relieve pain and also to improve the general well being and 
survival of the patient.
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KEY TO MASTER CHART
1. Sex Male- 1 Female - 2
2. CF-Clinical Features
Pain - 1
Constitutional Symptoms - 2
 Palpable Mass - 3
Ascites - 4
Jaundice - 5
3. Child Pugh Criteria
A - 1
B - 2
4.    Portal vein status
Patent - 1
Right branch involvement - 2
Left branch involvement - 3
Main Portal involvement - 4
5. Treatment
TACE - 1
Symptomatic management - 2
6. Pre VAS
Pre Treatment Visual Analogue Scale
7. Post Vas
Post Treatment Visual Analogue Scale
8. Pre Performance status scale
Pre Treatment PSS
9. Post PSS
Post Treatment PSS
10. Size Change after 1 month
No Change - 1
Reduction more than 20% - 2
Increase more than 20% - 3
11. 6 months Follow up 
Survived - 1
Died - 2
12. 12 months Follow up 
Survived - 1
Died - 2
13. Complications
Nil - 0
Post embolization Symptoms - 1
Liver Abscess - 2
Liver Cell Failure - 3
Catheter related complication - 4
14. Repeat TACE
Nil - 0
Present - 1
15. Died At  (in months)
ABBREVIATIONS
AFP - Alpha Feto Protein
CTA - CT Arteriography
CTAP - CT Arterial Portography
HCC -  Hepatocellular Carcinoma
PEI - Percutaneous Ethanol Injection
PSS - Performance Status Scale
RFA - Radio Frequency Ablation 
TACE - Transarterial Chemo Embolization
USG - Ultrasonogram
VAS - Visual Analog Scale
PROFORMA
 
Name:                                                        Age    :
Occupation      :                                     IP NO    :
 Presenting  complaints
     
            Constitutional symptoms yes/ no
             Abdominal pain                               yes/ no
             Palpable liver mass                         yes/ no 
 
             Ascites                                              yes/ no 
             Jaundice                                           yes/ no    
Past history:
   
            Cirrhosis         HBV       HCV         H/O primary
            Surgery       H/o Blood transfusion
Personal history:
            Smoker                                             yes/ no
             
             Alcoholic  yes/ no
          
Allergic History:                   yes/ no
General examination:
Anaemia
Jaundice
Lymphadenopathy
Systemic examination:
CVS  :
RS :
Abdomen:
    Hepatomegaly
    Splenomegaly
    Ascites
CLINICAL DIAGNOSIS:
INVESTIGATION:
Hemoglobin
Bleeding time, Clotting time
PT, APTT
Bilirubin
Serum albumin
Urea, creatinine
AFP
CHILD PUGH SCORE   A / B:
ULTRASONOGRAM   /  CT:
Lesion size
 
Number
Location
Echogenicity / Density
Portal vein involvement
Bile duct dilatation
Regional lymphadenopathy
Ascites
Color Duplex 
Intra lesional flow pattern 
Portal vein involvement 
Histopathology
TREATMENT:
                        TACE   /   SYMPTOMATIC
COMPLICATIONS:
POST TREATMENT FOLLOW UP:
 
At 1 month:
Pre treatment visual analogue scale   Post treatment visual analogue scale
Pre treatment performance status scale Post treatment performance status scale
Tumor size change:   ---  decreased/ increased / static
Repeat TACE :  yes / no
At 6 month:
Survival                 yes / no
At 12 month: 
Survival   yes / no                                                                           
PERFORMANCE STATUS SCALES
ECOG (Eastern Cooperative Oncology Group)
1. Asymptomatic; Normal Activity = 0
2. Symptomatic; ambulatory; able to carry = 1
out activities of daily living
3. Symptomatic; in bed less than 50%
of the day; occasionally needs nursing care = 2
4. Symptomatic; in bed more than 50%
of the day; needs nursing care = 3
5. Bedridden; may need hospitalization = 4
